Moderna and Merck announced positive Phase 3 trial results for intismeran, an individualized cancer vaccine designed to work alongside the immunotherapy Keytruda in melanoma patients following surgery. The announcement triggered substantial market enthusiasm, with Moderna shares rising more than 170% in a single day, adding nearly $45 billion to the company’s market capitalization. Partner Merck’s shares and those of rival BioNTech, which develops similar vaccine technology, also experienced double-digit gains.
The vaccine works by stimulating immune responses against 34 unique protein markers found on tumor surfaces. The trial tested the combination therapy in the adjuvant setting, meaning after tumor removal, with the goal of reducing cancer recurrence compared to Keytruda monotherapy. While the companies did not release specific data, preliminary mid-stage results presented earlier this year suggested the combination roughly halved the risk of relapse or death over five years of follow-up. Detailed Phase 3 data will be presented at a future medical conference.
Multiple analysts upgraded their outlooks on the companies involved. One analyst projected Moderna could eventually achieve $5.4 billion in peak annual melanoma sales from its 50-50 revenue split with Merck on intismeran. The positive result also elevated expectations for nine additional ongoing trials the partners are conducting in other cancer types, including kidney, bladder, and lung cancers, with mid-stage kidney and bladder results potentially coming later this year or in 2027.
However, some analysts cautioned that the stock market’s euphoric reaction may have overestimated intismeran’s commercial potential and therapeutic efficacy. Concerns included the possibility that manufacturing costs for personalized vaccines could exceed those of standard biologics, and that success in melanoma might not translate to other tumor types. Several market observers warned the valuation already reflected substantial optimism relative to disclosed data and expressed skepticism about whether future results could meet heightened expectations.
Article Attribution | Read More at Article Source
Article summary produced by Claude AI